Global Human Microbiome Therapeutic Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 88

Published Date: 07 Jan 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Human microbiome therapeutic drugs are drugs made by using the relationship between the gene content of the microbiota and metabolic activities.

According to our (Global Info Research) latest study, the global Human Microbiome Therapeutic Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Human Microbiome Therapeutic Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Human Microbiome Therapeutic Drugs market size and forecasts, in consumption value ($ Million), 2018-2029
Global Human Microbiome Therapeutic Drugs market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Human Microbiome Therapeutic Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Human Microbiome Therapeutic Drugs market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Microbiome Therapeutic Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Microbiome Therapeutic Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb and Johnson and Johnson, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Human Microbiome Therapeutic Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    FMT
    Microbiome Drugs
    Others

Market segment by Application
    Stomach
    Oral
    Respiratory Tract
    Others

Market segment by players, this report covers
    Rebiotix
    Seres Therapeutics
    Vedanta Biosciences
    Bristol-Myers Squibb
    Johnson and Johnson
    Takeda
    ENTEROME Bioscience

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Human Microbiome Therapeutic Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Human Microbiome Therapeutic Drugs, with revenue, gross margin and global market share of Human Microbiome Therapeutic Drugs from 2018 to 2023.
Chapter 3, the Human Microbiome Therapeutic Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Human Microbiome Therapeutic Drugs market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Human Microbiome Therapeutic Drugs.
Chapter 13, to describe Human Microbiome Therapeutic Drugs research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Human Microbiome Therapeutic Drugs
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Human Microbiome Therapeutic Drugs by Type
        1.3.1 Overview: Global Human Microbiome Therapeutic Drugs Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Human Microbiome Therapeutic Drugs Consumption Value Market Share by Type in 2022
        1.3.3 FMT
        1.3.4 Microbiome Drugs
        1.3.5 Others
    1.4 Global Human Microbiome Therapeutic Drugs Market by Application
        1.4.1 Overview: Global Human Microbiome Therapeutic Drugs Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Stomach
        1.4.3 Oral
        1.4.4 Respiratory Tract
        1.4.5 Others
    1.5 Global Human Microbiome Therapeutic Drugs Market Size & Forecast
    1.6 Global Human Microbiome Therapeutic Drugs Market Size and Forecast by Region
        1.6.1 Global Human Microbiome Therapeutic Drugs Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Human Microbiome Therapeutic Drugs Market Size by Region, (2018-2029)
        1.6.3 North America Human Microbiome Therapeutic Drugs Market Size and Prospect (2018-2029)
        1.6.4 Europe Human Microbiome Therapeutic Drugs Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Human Microbiome Therapeutic Drugs Market Size and Prospect (2018-2029)
        1.6.6 South America Human Microbiome Therapeutic Drugs Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Human Microbiome Therapeutic Drugs Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Rebiotix
        2.1.1 Rebiotix Details
        2.1.2 Rebiotix Major Business
        2.1.3 Rebiotix Human Microbiome Therapeutic Drugs Product and Solutions
        2.1.4 Rebiotix Human Microbiome Therapeutic Drugs Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Rebiotix Recent Developments and Future Plans
    2.2 Seres Therapeutics
        2.2.1 Seres Therapeutics Details
        2.2.2 Seres Therapeutics Major Business
        2.2.3 Seres Therapeutics Human Microbiome Therapeutic Drugs Product and Solutions
        2.2.4 Seres Therapeutics Human Microbiome Therapeutic Drugs Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Seres Therapeutics Recent Developments and Future Plans
    2.3 Vedanta Biosciences
        2.3.1 Vedanta Biosciences Details
        2.3.2 Vedanta Biosciences Major Business
        2.3.3 Vedanta Biosciences Human Microbiome Therapeutic Drugs Product and Solutions
        2.3.4 Vedanta Biosciences Human Microbiome Therapeutic Drugs Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Vedanta Biosciences Recent Developments and Future Plans
    2.4 Bristol-Myers Squibb
        2.4.1 Bristol-Myers Squibb Details
        2.4.2 Bristol-Myers Squibb Major Business
        2.4.3 Bristol-Myers Squibb Human Microbiome Therapeutic Drugs Product and Solutions
        2.4.4 Bristol-Myers Squibb Human Microbiome Therapeutic Drugs Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
    2.5 Johnson and Johnson
        2.5.1 Johnson and Johnson Details
        2.5.2 Johnson and Johnson Major Business
        2.5.3 Johnson and Johnson Human Microbiome Therapeutic Drugs Product and Solutions
        2.5.4 Johnson and Johnson Human Microbiome Therapeutic Drugs Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Johnson and Johnson Recent Developments and Future Plans
    2.6 Takeda
        2.6.1 Takeda Details
        2.6.2 Takeda Major Business
        2.6.3 Takeda Human Microbiome Therapeutic Drugs Product and Solutions
        2.6.4 Takeda Human Microbiome Therapeutic Drugs Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Takeda Recent Developments and Future Plans
    2.7 ENTEROME Bioscience
        2.7.1 ENTEROME Bioscience Details
        2.7.2 ENTEROME Bioscience Major Business
        2.7.3 ENTEROME Bioscience Human Microbiome Therapeutic Drugs Product and Solutions
        2.7.4 ENTEROME Bioscience Human Microbiome Therapeutic Drugs Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 ENTEROME Bioscience Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Human Microbiome Therapeutic Drugs Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Human Microbiome Therapeutic Drugs by Company Revenue
        3.2.2 Top 3 Human Microbiome Therapeutic Drugs Players Market Share in 2022
        3.2.3 Top 6 Human Microbiome Therapeutic Drugs Players Market Share in 2022
    3.3 Human Microbiome Therapeutic Drugs Market: Overall Company Footprint Analysis
        3.3.1 Human Microbiome Therapeutic Drugs Market: Region Footprint
        3.3.2 Human Microbiome Therapeutic Drugs Market: Company Product Type Footprint
        3.3.3 Human Microbiome Therapeutic Drugs Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Human Microbiome Therapeutic Drugs Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Human Microbiome Therapeutic Drugs Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Human Microbiome Therapeutic Drugs Consumption Value Market Share by Application (2018-2023)
    5.2 Global Human Microbiome Therapeutic Drugs Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2029)
    6.2 North America Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2029)
    6.3 North America Human Microbiome Therapeutic Drugs Market Size by Country
        6.3.1 North America Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2029)
        6.3.2 United States Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        6.3.3 Canada Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        6.3.4 Mexico Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2029)
    7.2 Europe Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2029)
    7.3 Europe Human Microbiome Therapeutic Drugs Market Size by Country
        7.3.1 Europe Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2029)
        7.3.2 Germany Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        7.3.3 France Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        7.3.5 Russia Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        7.3.6 Italy Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Human Microbiome Therapeutic Drugs Market Size by Region
        8.3.1 Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Region (2018-2029)
        8.3.2 China Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        8.3.3 Japan Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        8.3.4 South Korea Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        8.3.5 India Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        8.3.7 Australia Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2029)
    9.2 South America Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2029)
    9.3 South America Human Microbiome Therapeutic Drugs Market Size by Country
        9.3.1 South America Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2029)
        9.3.2 Brazil Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        9.3.3 Argentina Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Human Microbiome Therapeutic Drugs Market Size by Country
        10.3.1 Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2029)
        10.3.2 Turkey Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)
        10.3.4 UAE Human Microbiome Therapeutic Drugs Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Human Microbiome Therapeutic Drugs Market Drivers
    11.2 Human Microbiome Therapeutic Drugs Market Restraints
    11.3 Human Microbiome Therapeutic Drugs Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Human Microbiome Therapeutic Drugs Industry Chain
    12.2 Human Microbiome Therapeutic Drugs Upstream Analysis
    12.3 Human Microbiome Therapeutic Drugs Midstream Analysis
    12.4 Human Microbiome Therapeutic Drugs Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Human Microbiome Therapeutic Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Human Microbiome Therapeutic Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Human Microbiome Therapeutic Drugs Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Human Microbiome Therapeutic Drugs Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Rebiotix Company Information, Head Office, and Major Competitors
    Table 6. Rebiotix Major Business
    Table 7. Rebiotix Human Microbiome Therapeutic Drugs Product and Solutions
    Table 8. Rebiotix Human Microbiome Therapeutic Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Rebiotix Recent Developments and Future Plans
    Table 10. Seres Therapeutics Company Information, Head Office, and Major Competitors
    Table 11. Seres Therapeutics Major Business
    Table 12. Seres Therapeutics Human Microbiome Therapeutic Drugs Product and Solutions
    Table 13. Seres Therapeutics Human Microbiome Therapeutic Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Seres Therapeutics Recent Developments and Future Plans
    Table 15. Vedanta Biosciences Company Information, Head Office, and Major Competitors
    Table 16. Vedanta Biosciences Major Business
    Table 17. Vedanta Biosciences Human Microbiome Therapeutic Drugs Product and Solutions
    Table 18. Vedanta Biosciences Human Microbiome Therapeutic Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Vedanta Biosciences Recent Developments and Future Plans
    Table 20. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
    Table 21. Bristol-Myers Squibb Major Business
    Table 22. Bristol-Myers Squibb Human Microbiome Therapeutic Drugs Product and Solutions
    Table 23. Bristol-Myers Squibb Human Microbiome Therapeutic Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Bristol-Myers Squibb Recent Developments and Future Plans
    Table 25. Johnson and Johnson Company Information, Head Office, and Major Competitors
    Table 26. Johnson and Johnson Major Business
    Table 27. Johnson and Johnson Human Microbiome Therapeutic Drugs Product and Solutions
    Table 28. Johnson and Johnson Human Microbiome Therapeutic Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Johnson and Johnson Recent Developments and Future Plans
    Table 30. Takeda Company Information, Head Office, and Major Competitors
    Table 31. Takeda Major Business
    Table 32. Takeda Human Microbiome Therapeutic Drugs Product and Solutions
    Table 33. Takeda Human Microbiome Therapeutic Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. Takeda Recent Developments and Future Plans
    Table 35. ENTEROME Bioscience Company Information, Head Office, and Major Competitors
    Table 36. ENTEROME Bioscience Major Business
    Table 37. ENTEROME Bioscience Human Microbiome Therapeutic Drugs Product and Solutions
    Table 38. ENTEROME Bioscience Human Microbiome Therapeutic Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. ENTEROME Bioscience Recent Developments and Future Plans
    Table 40. Global Human Microbiome Therapeutic Drugs Revenue (USD Million) by Players (2018-2023)
    Table 41. Global Human Microbiome Therapeutic Drugs Revenue Share by Players (2018-2023)
    Table 42. Breakdown of Human Microbiome Therapeutic Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 43. Market Position of Players in Human Microbiome Therapeutic Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 44. Head Office of Key Human Microbiome Therapeutic Drugs Players
    Table 45. Human Microbiome Therapeutic Drugs Market: Company Product Type Footprint
    Table 46. Human Microbiome Therapeutic Drugs Market: Company Product Application Footprint
    Table 47. Human Microbiome Therapeutic Drugs New Market Entrants and Barriers to Market Entry
    Table 48. Human Microbiome Therapeutic Drugs Mergers, Acquisition, Agreements, and Collaborations
    Table 49. Global Human Microbiome Therapeutic Drugs Consumption Value (USD Million) by Type (2018-2023)
    Table 50. Global Human Microbiome Therapeutic Drugs Consumption Value Share by Type (2018-2023)
    Table 51. Global Human Microbiome Therapeutic Drugs Consumption Value Forecast by Type (2024-2029)
    Table 52. Global Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2023)
    Table 53. Global Human Microbiome Therapeutic Drugs Consumption Value Forecast by Application (2024-2029)
    Table 54. North America Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2023) & (USD Million)
    Table 55. North America Human Microbiome Therapeutic Drugs Consumption Value by Type (2024-2029) & (USD Million)
    Table 56. North America Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2023) & (USD Million)
    Table 57. North America Human Microbiome Therapeutic Drugs Consumption Value by Application (2024-2029) & (USD Million)
    Table 58. North America Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2023) & (USD Million)
    Table 59. North America Human Microbiome Therapeutic Drugs Consumption Value by Country (2024-2029) & (USD Million)
    Table 60. Europe Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2023) & (USD Million)
    Table 61. Europe Human Microbiome Therapeutic Drugs Consumption Value by Type (2024-2029) & (USD Million)
    Table 62. Europe Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2023) & (USD Million)
    Table 63. Europe Human Microbiome Therapeutic Drugs Consumption Value by Application (2024-2029) & (USD Million)
    Table 64. Europe Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2023) & (USD Million)
    Table 65. Europe Human Microbiome Therapeutic Drugs Consumption Value by Country (2024-2029) & (USD Million)
    Table 66. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2023) & (USD Million)
    Table 67. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Type (2024-2029) & (USD Million)
    Table 68. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2023) & (USD Million)
    Table 69. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Application (2024-2029) & (USD Million)
    Table 70. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Region (2018-2023) & (USD Million)
    Table 71. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value by Region (2024-2029) & (USD Million)
    Table 72. South America Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2023) & (USD Million)
    Table 73. South America Human Microbiome Therapeutic Drugs Consumption Value by Type (2024-2029) & (USD Million)
    Table 74. South America Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2023) & (USD Million)
    Table 75. South America Human Microbiome Therapeutic Drugs Consumption Value by Application (2024-2029) & (USD Million)
    Table 76. South America Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2023) & (USD Million)
    Table 77. South America Human Microbiome Therapeutic Drugs Consumption Value by Country (2024-2029) & (USD Million)
    Table 78. Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Type (2018-2023) & (USD Million)
    Table 79. Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Type (2024-2029) & (USD Million)
    Table 80. Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Application (2018-2023) & (USD Million)
    Table 81. Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Application (2024-2029) & (USD Million)
    Table 82. Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Country (2018-2023) & (USD Million)
    Table 83. Middle East & Africa Human Microbiome Therapeutic Drugs Consumption Value by Country (2024-2029) & (USD Million)
    Table 84. Human Microbiome Therapeutic Drugs Raw Material
    Table 85. Key Suppliers of Human Microbiome Therapeutic Drugs Raw Materials
List of Figures
    Figure 1. Human Microbiome Therapeutic Drugs Picture
    Figure 2. Global Human Microbiome Therapeutic Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Human Microbiome Therapeutic Drugs Consumption Value Market Share by Type in 2022
    Figure 4. FMT
    Figure 5. Microbiome Drugs
    Figure 6. Others
    Figure 7. Global Human Microbiome Therapeutic Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 8. Human Microbiome Therapeutic Drugs Consumption Value Market Share by Application in 2022
    Figure 9. Stomach Picture
    Figure 10. Oral Picture
    Figure 11. Respiratory Tract Picture
    Figure 12. Others Picture
    Figure 13. Global Human Microbiome Therapeutic Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 14. Global Human Microbiome Therapeutic Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 15. Global Market Human Microbiome Therapeutic Drugs Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 16. Global Human Microbiome Therapeutic Drugs Consumption Value Market Share by Region (2018-2029)
    Figure 17. Global Human Microbiome Therapeutic Drugs Consumption Value Market Share by Region in 2022
    Figure 18. North America Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 20. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 21. South America Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 22. Middle East and Africa Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 23. Global Human Microbiome Therapeutic Drugs Revenue Share by Players in 2022
    Figure 24. Human Microbiome Therapeutic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 25. Global Top 3 Players Human Microbiome Therapeutic Drugs Market Share in 2022
    Figure 26. Global Top 6 Players Human Microbiome Therapeutic Drugs Market Share in 2022
    Figure 27. Global Human Microbiome Therapeutic Drugs Consumption Value Share by Type (2018-2023)
    Figure 28. Global Human Microbiome Therapeutic Drugs Market Share Forecast by Type (2024-2029)
    Figure 29. Global Human Microbiome Therapeutic Drugs Consumption Value Share by Application (2018-2023)
    Figure 30. Global Human Microbiome Therapeutic Drugs Market Share Forecast by Application (2024-2029)
    Figure 31. North America Human Microbiome Therapeutic Drugs Consumption Value Market Share by Type (2018-2029)
    Figure 32. North America Human Microbiome Therapeutic Drugs Consumption Value Market Share by Application (2018-2029)
    Figure 33. North America Human Microbiome Therapeutic Drugs Consumption Value Market Share by Country (2018-2029)
    Figure 34. United States Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 35. Canada Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 36. Mexico Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 37. Europe Human Microbiome Therapeutic Drugs Consumption Value Market Share by Type (2018-2029)
    Figure 38. Europe Human Microbiome Therapeutic Drugs Consumption Value Market Share by Application (2018-2029)
    Figure 39. Europe Human Microbiome Therapeutic Drugs Consumption Value Market Share by Country (2018-2029)
    Figure 40. Germany Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 41. France Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 42. United Kingdom Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 43. Russia Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 44. Italy Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 45. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value Market Share by Type (2018-2029)
    Figure 46. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value Market Share by Application (2018-2029)
    Figure 47. Asia-Pacific Human Microbiome Therapeutic Drugs Consumption Value Market Share by Region (2018-2029)
    Figure 48. China Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 49. Japan Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 50. South Korea Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 51. India Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 52. Southeast Asia Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 53. Australia Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 54. South America Human Microbiome Therapeutic Drugs Consumption Value Market Share by Type (2018-2029)
    Figure 55. South America Human Microbiome Therapeutic Drugs Consumption Value Market Share by Application (2018-2029)
    Figure 56. South America Human Microbiome Therapeutic Drugs Consumption Value Market Share by Country (2018-2029)
    Figure 57. Brazil Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 58. Argentina Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 59. Middle East and Africa Human Microbiome Therapeutic Drugs Consumption Value Market Share by Type (2018-2029)
    Figure 60. Middle East and Africa Human Microbiome Therapeutic Drugs Consumption Value Market Share by Application (2018-2029)
    Figure 61. Middle East and Africa Human Microbiome Therapeutic Drugs Consumption Value Market Share by Country (2018-2029)
    Figure 62. Turkey Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 63. Saudi Arabia Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 64. UAE Human Microbiome Therapeutic Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 65. Human Microbiome Therapeutic Drugs Market Drivers
    Figure 66. Human Microbiome Therapeutic Drugs Market Restraints
    Figure 67. Human Microbiome Therapeutic Drugs Market Trends
    Figure 68. Porters Five Forces Analysis
    Figure 69. Manufacturing Cost Structure Analysis of Human Microbiome Therapeutic Drugs in 2022
    Figure 70. Manufacturing Process Analysis of Human Microbiome Therapeutic Drugs
    Figure 71. Human Microbiome Therapeutic Drugs Industrial Chain
    Figure 72. Methodology
    Figure 73. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Rebiotix
Seres Therapeutics
Vedanta Biosciences
Bristol-Myers Squibb
Johnson and Johnson
Takeda
ENTEROME Bioscience

Related Reports

Global Human Microbiome Therapeutic Drugs Supply, Demand and Key Producers, 2023-2029

Global Human Microbiome Therapeutic Drugs Supply, Demand and Key Producers, 2023-2029

date 19 Jan 2023

date Medical Care

The global Human Microbiome Therapeutic Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Human Microbiome Therapeutic Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Human Microbiome Therapeutic Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Human Microbiome Therapeutic Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

Human Microbiome Therapeutic Drugs

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>